OrchidPharma net debt reaches Rs 487 crore on project funding
Key highlights
- OrchidPharma reported consolidated net debt of Rs 487 crore at 30 September 2026, versus Rs 218 crore at 31 March 2026.
- Consolidated gross borrowings increased by Rs 242.22 crore to Rs 543.66 crore during the six months to September 2026.
- Consolidated capital work-in-progress rose by Rs 347.60 crore to Rs 688.12 crore, led by 7ACA and Cefiderocol projects.
- OrchidPharma generated Rs 117.78 crore of consolidated operating cash in H1 FY27 while investing activities used Rs 314.58 crore.
powered by IRIS

OrchidPharma reported consolidated net debt of Rs 487 crore at 30 September 2026, up from Rs 218 crore at 31 March 2026, after capital work-in-progress rose to Rs 688.12 crore. The presentation says non-current assets increased largely because of work on the 7ACA and Cefiderocol projects, funded partly through incremental borrowings.
Know Orchid Pharma inside out
Results, valuation, peers and who's buying, in one view.
How much did OrchidPharma’s debt increase by September 2026?
OrchidPharma’s consolidated gross borrowings increased to Rs 543.66 crore at 30 September 2026 from Rs 301.44 crore at 31 March 2026, a rise of Rs 242.22 crore. The presentation separately reports net debt of Rs 487 crore, versus Rs 218 crore six months earlier, while the debt-to-equity ratio increased to 0.33x from 0.19x.
The borrowing increase occurred in both maturity categories. Non-current borrowings rose by Rs 154.32 crore to Rs 339.06 crore, while current borrowings increased by Rs 87.90 crore to Rs 204.60 crore. Consolidated equity rose by Rs 67.97 crore to Rs 1,632.28 crore, comprising Rs 59.89 crore of equity share capital and Rs 1,572.40 crore of other equity.
Cash and cash equivalents were Rs 46.62 crore at 30 September 2026, compared with Rs 7.07 crore at 31 March 2026, while other bank balances fell to Rs 9.65 crore from Rs 76.45 crore. The presentation reports the Rs 487 crore net-debt figure but does not provide a line-by-line reconciliation of that measure.
What projects drove OrchidPharma’s asset expansion?
OrchidPharma says its Rs 368 crore increase in consolidated non-current assets was led by capital work-in-progress on the 7ACA and Cefiderocol projects. Consolidated capital work-in-progress rose by Rs 347.60 crore to Rs 688.12 crore at 30 September 2026 from Rs 340.52 crore at 31 March 2026.
Property, plant and equipment increased by Rs 35.59 crore to Rs 722.20 crore, while intangible assets increased by Rs 1.68 crore to Rs 62.28 crore. In contrast, intangibles under development declined by Rs 48.10 crore to Rs 24.98 crore, and total consolidated assets increased by Rs 393.92 crore to Rs 2,652.35 crore.
The standalone balance sheet shows a different allocation of investment. Standalone capital work-in-progress rose by Rs 101.12 crore to Rs 196.12 crore, while loans to subsidiaries increased by Rs 180.16 crore to Rs 362.65 crore between 31 March and 30 September 2026. These intra-group loans are not presented as assets in the consolidated balance sheet, which reports the group’s Rs 688.12 crore capital work-in-progress balance.
How was OrchidPharma’s first-half investment funded?
OrchidPharma generated Rs 117.78 crore of consolidated net cash from operating activities in H1 FY27 ended 30 September 2026, compared with an outflow of Rs 4.70 crore in H1 FY26. Its consolidated investing cash outflow was Rs 314.58 crore in H1 FY27, compared with Rs 72.48 crore in the previous first half.
Financing activities generated Rs 236.34 crore of cash in H1 FY27, compared with Rs 98.08 crore in H1 FY26. Operating and financing inflows together exceeded the Rs 314.58 crore investing outflow, resulting in a Rs 39.55 crore increase in consolidated cash and cash equivalents to Rs 46.62 crore.
Working-capital movements contributed Rs 62.54 crore to consolidated operating cash generation in H1 FY27, whereas they used Rs 11.98 crore in H1 FY26. Inventories increased by Rs 49.80 crore to Rs 422.11 crore during the six months, while trade receivables declined by Rs 33.19 crore to Rs 348.16 crore.
Got a follow-up? Ask IRIS
Did higher borrowing coincide with improved profitability?
OrchidPharma reported consolidated profit of Rs 31.82 crore for H1 FY27, compared with a loss of Rs 6.59 crore in H1 FY26. Revenue from operations increased by Rs 83.80 crore to Rs 645.44 crore, while consolidated profit before tax turned to Rs 29.49 crore from a loss before tax of Rs 5.55 crore.
The standalone statement reported profit before tax and profit for the period of Rs 48.70 crore in H1 FY27, up from Rs 4.50 crore in H1 FY26. Consolidated other income declined to Rs 19.58 crore from Rs 23.21 crore, while the share of profit from associates and joint ventures was Rs 2.36 crore after a Rs 1.19 crore share of loss a year earlier.
Consolidated finance costs were Rs 5.87 crore in H1 FY27, compared with Rs 4.85 crore in H1 FY26. The presentation provides the half-year finance-cost figure and the 30 September 2026 borrowing balance, but it does not disclose borrowing rates, repayment schedules or the cost of either project.
What remains undisclosed about OrchidPharma’s project funding?
OrchidPharma identifies 7ACA and Cefiderocol as the drivers of the increase in non-current assets, with consolidated capital work-in-progress reaching Rs 688.12 crore at 30 September 2026. It does not disclose project completion dates, commissioning milestones, expected revenue, or the projects’ total capital cost.
The next reported balance sheets will show whether capital work-in-progress moves into property, plant and equipment after the Rs 347.60 crore first-half increase. Subsequent cash-flow statements will also show whether operating cash generation, which was Rs 117.78 crore in H1 FY27, continues to cover a larger portion of investment spending.
Conclusion
OrchidPharma paired a return to consolidated profit in H1 FY27 with a substantial expansion in construction assets. Capital work-in-progress increased by Rs 347.60 crore, gross borrowings rose by Rs 242.22 crore, and reported net debt reached Rs 487 crore at 30 September 2026.
The disclosed matter to watch is progress on the 7ACA and Cefiderocol projects, which drove the Rs 368 crore increase in non-current assets. The presentation gives no completion schedule, capital-cost target, expected commercial contribution or debt-reduction plan, making future movements in the Rs 688.12 crore capital work-in-progress balance and Rs 487 crore net debt relevant measures of progress.


